Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Drug Updates, Trials, Safety Data

  |  Issue: June 2014  |  

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York, a pharmacist at New York Presbyterian—Lower Manhattan Hospital, and adjunct faculty at Touro College of Pharmacy.

References

  1. Delaware passes biosimilars substitution law. Generics and Biosimilars Initiative (GaBI). April 25, 2014. http://gabionline.net/Policies-Legislation/Delaware-passes-biosimilars-substitution-law?utm_source=GONL4&utm_campaign=1bd991b2c7-GONL+V14D25-4&utm_medium=email&utm_term=0_c68e980169-1bd991b2c7-111320173 certain restrictions. Last accessed April 25, 2014.
  2. Indiana biosimilars substitution becomes law. Generics and Biosimilars Initiative (GaBI). March 28, 2014. http://gabionline.net/Policies-Legislation/Indiana-biosimilars-substitution-bill-becomes-law. Last accessed April 25, 2014.
  3. Biosimilars bills move on in two states. Generics and Biosimilars Initiative (GaBI). March 15, 2013. http://www.gabionline.net/Policies-Legislation/Biosimilars-bills-move-on-in-two-US-states. Last accessed April 25, 2014.
  4. US state legislation on biosimilars substitution. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(3):155–156. Available at http://gabi-journal.net/us-state-legislation-on-biosimilars-substitution.html.
  5. Biosimilar rituximab approved in Russia. Generics and Biosimilars Initiative (GaBI). April 25, 2014. http://gabionline.net/Biosimilars/News/Biosimilar-rituximab-approved-in-Russia?utm_source=GONL4&utm_campaign=1bd991b2c7-GONL+V14D25-4&utm_medium=email&utm_term=0_c68e980169-1bd991b2c7-111320173. Last accessed April 25, 2014.
  6. George J. Teva and Pfizer settle Celebrex patent dispute. Philadelphia Business Journal. April 17, 2014. http://www.bizjournals.com/philadelphia/blog/health-care/2014/04/teva-and-pfizer-settle-celebrex-patent-dispute.html?surround=etf&ana=e_article. Last accessed April 25, 2014.
  7. Xoma to halt development of Gevokizumab in osteoarthritis indication. Genetic Engineering & Biotechnology News. March 5, 2014. http://www.genengnews.com/gen-news-highlights/xoma-to-halt-development-of-gevokizumab-in-osteoarthritis-indication/81249581. Last accessed April 25, 2014.
  8. Manocha V. Xoma to stop testing drug as arthritis treatment; shares plunge. Reuters. March 5, 2014. http://mobile.reuters.com/article/idUSBREA241IP20140305?irpc=932. Last accessed April 25, 2014.
  9. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of a randomised, placebo-controlled trial, the GO-REVEAL study. Ann Rheum Dis. 2014 April 19. doi: 10.1136/annrheumdis-2013-204902. http://ard.bmj.com/content/early/2014/04/26/annrheumdis-2013-204902.full.
  10. Armstrong D. Purdue pill may force Zogenix’s rival drug off market. Bloomberg. March 12, 2014. http://mobile.bloomberg.com/news/2014-03-12/purdue-pill-may-force-zogenix-s-rival-drug-off-market.html. Last accessed April 25, 2014.
  11. Iroko Pharmaceuticals receives FDA approval for Tivorbex. Iroko Pharmaceuticals. Feb. 24, 2014. https://www.iroko.com/press-releases/iroko-pharmaceuticals-receives-fda-approval-for-tivorbex. Last accessed April 25, 2014.
  12. Chavis R. Kremers Urban launches rabeprazole sodium tablets. Drug Store News. Feb. 20, 2014. http://www.drugstorenews.com/article/kremers-urban-launches-rabeprazole-sodium-tablets. Last accessed April 25, 2014.
  13. Chavis R. Teva approved for generic Evista. Drug Store News. March 4, 2014 http://www.drugstorenews.com/article/teva-approved-generic-evista. Last accessed April 25, 2014.
  14. Epidural corticosteroid injection: Drug safety communication—Risk of rare but serious neurologic problems. U.S. Food and Drug Administration. April 23, 2014. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm394530.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Last accessed April 25, 2014.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles
    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…